Glucose-Regulated Protein 94 (GRP94): A Novel Regulator of Insulin-Like Growth Factor Production
Research output: Contribution to journal › Review › Research › peer-review
Standard
Glucose-Regulated Protein 94 (GRP94) : A Novel Regulator of Insulin-Like Growth Factor Production. / Argon, Yair; Bresson, Sophie E.; Marzec, Michal T.; Grimberg, Adda.
In: Cells, Vol. 9, No. 8, 1844, 2020.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucose-Regulated Protein 94 (GRP94)
T2 - A Novel Regulator of Insulin-Like Growth Factor Production
AU - Argon, Yair
AU - Bresson, Sophie E.
AU - Marzec, Michal T.
AU - Grimberg, Adda
PY - 2020
Y1 - 2020
N2 - Mammals have two insulin-like growth factors (IGF) that are key mediators of somatic growth, tissue differentiation, and cellular responses to stress. Thus, the mechanisms that regulate the bioavailability of IGFs are important in both normal and aberrant development. IGF-I levels are primarily controlled via the growth hormone-IGF axis, in response to nutritional status, and also reflect metabolic diseases and cancer. One mechanism that controls IGF bioavailablity is the binding of circulating IGF to a number of binding proteins that keep IGF in a stable, but receptor non-binding state. However, even before IGF is released from the cells that produce it, it undergoes an obligatory association with a ubiquitous chaperone protein, GRP94. This binding is required for secretion of a properly folded, mature IGF. This chapter reviews the known aspects of the interaction and highlights the specificity issues yet to be determined. The IGF-GRP94 interaction provides a potential novel mechanism of idiopathic short stature, involving the obligatory chaperone and not just IGF gene expression. It also provides a novel target for cancer treatment, as GRP94 activity can be either inhibited or enhanced.
AB - Mammals have two insulin-like growth factors (IGF) that are key mediators of somatic growth, tissue differentiation, and cellular responses to stress. Thus, the mechanisms that regulate the bioavailability of IGFs are important in both normal and aberrant development. IGF-I levels are primarily controlled via the growth hormone-IGF axis, in response to nutritional status, and also reflect metabolic diseases and cancer. One mechanism that controls IGF bioavailablity is the binding of circulating IGF to a number of binding proteins that keep IGF in a stable, but receptor non-binding state. However, even before IGF is released from the cells that produce it, it undergoes an obligatory association with a ubiquitous chaperone protein, GRP94. This binding is required for secretion of a properly folded, mature IGF. This chapter reviews the known aspects of the interaction and highlights the specificity issues yet to be determined. The IGF-GRP94 interaction provides a potential novel mechanism of idiopathic short stature, involving the obligatory chaperone and not just IGF gene expression. It also provides a novel target for cancer treatment, as GRP94 activity can be either inhibited or enhanced.
KW - glucose regulated protein (GRP) 94
KW - insulin-like growth factor
KW - obligate chaperone
KW - I IGF-I
KW - TOLL-LIKE RECEPTORS
KW - ENDOPLASMIC-RETICULUM
KW - CHAPERONE ACTIVITY
KW - REFERENCE VALUES
KW - SHORT STATURE
KW - C-ELEGANS
KW - BINDING
KW - HORMONE
KW - GP96
U2 - 10.3390/cells9081844
DO - 10.3390/cells9081844
M3 - Review
C2 - 32781621
VL - 9
JO - Cells
JF - Cells
SN - 2073-4409
IS - 8
M1 - 1844
ER -
ID: 249816635